These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 15908659)

  • 1. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
    Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
    J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
    Perez-Soler R; Lopez-Berestein G; Lautersztain J; al-Baker S; Francis K; Macias-Kiger D; Raber MN; Khokhar AR
    Cancer Res; 1990 Jul; 50(14):4254-9. PubMed ID: 2364384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant pleural mesothelioma: surgical management in 285 patients.
    Schipper PH; Nichols FC; Thomse KM; Deschamps C; Cassivi SD; Allen MS; Pairolero PC
    Ann Thorac Surg; 2008 Jan; 85(1):257-64; discussion 264. PubMed ID: 18154820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
    Neragi-Miandoab S; Richards WG; Sugarbaker DJ
    Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
    Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
    Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
    Flores RM; Pass HI; Seshan VE; Dycoco J; Zakowski M; Carbone M; Bains MS; Rusch VW
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):620-6, 626.e1-3. PubMed ID: 18329481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
    Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
    Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
    Tilleman TR; Richards WG; Zellos L; Johnson BE; Jaklitsch MT; Mueller J; Yeap BY; Mujoomdar AA; Ducko CT; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2009 Aug; 138(2):405-11. PubMed ID: 19619785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
    Halstead JC; Lim E; Venkateswaran RM; Charman SC; Goddard M; Ritchie AJ
    Eur J Surg Oncol; 2005 Apr; 31(3):314-20. PubMed ID: 15780570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
    Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
    Hillerdal G; Sorensen JB; Sundström S; Vikström A; Hjerpe A
    Clin Respir J; 2008 Apr; 2(2):80-5. PubMed ID: 20298311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
    van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
    J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
    Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
    Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.